Aβ-degrading enzymes: Potential for treatment of alzheimer disease

Journal of Neuropathology and Experimental Neurology

Volumn 70, Issue 11, 2011, Pages 944-959

  Miners, James Scott ^a   Barua, Neil ^a   Kehoe, Patrick Gavin ^a   Gill, Steven ^a   Love, Seth ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

A degrading enzymes; Alzheimer disease treatment; Cathepsin B; Convection enhanced delivery,Mouse models; Neprilysin

Indexed keywords

AMYLOID BETA PROTEIN; ENDOTHELIN CONVERTING ENZYME; GREEN TEA EXTRACT; IMATINIB; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE;

ALZHEIMER DISEASE; COGNITIVE DEFECT; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME RELEASE; GENE TARGETING; GENE THERAPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MICROGLIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STEM CELL TRANSPLANTATION; TRANSCRIPTION REGULATION; VASCULAR AMYLOIDOSIS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE MODELS, ANIMAL; GENE THERAPY; GLYCOPEPTIDES; HUMANS; INSULYSIN; MICE; MICE, TRANSGENIC; MICROGLIA; NEPRILYSIN; PROTEASE INHIBITORS; STEM CELL TRANSPLANTATION; THIORPHAN;

EID: 80054891306     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3182345e46     Document Type: Review

References (278)

1. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid A-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996;2:864-70 (Pubitemid 26296755)
2. Hutton M, Hardy J. The presenilins and Alzheimer's disease. Hum Mol Genet 1997;6:1639-46 (Pubitemid 27401606)
3. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997;20:154-59 (Pubitemid 27116286)
4. Eckman CB, Mehta ND, Crook R, et al. A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of AA42 (43). Hum Mol Genet 1997;6:2087-89 (Pubitemid 27477950)
5. Bateman RJ, Munsell LY, Morris JC, et al. Human amyloid-A synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 2006;12:856-61 (Pubitemid 44050079)
6. Zhao J, Fu Y, Yasvoina M, et al. A-Site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: Implications for Alzheimer's disease pathogenesis. J Neurosci 2007;27:3639-49 (Pubitemid 46557686)
7. Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS A-amyloid in Alzheimer's disease. Science 2010;330:1774
8. Weller RO, Preston SD, Subash M, et al. Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. Alzheimers Res Ther 2009;1:6
9. Weller RO, Massey A, Kuo YM, et al. Cerebral amyloid angiopathy: Accumulation of AA in interstitial fluid drainage pathways in Alzheimer's disease. Ann N Y Acad Sci 2000;903:110-17 (Pubitemid 30251546)
10. Preston SD, Steart PV, Wilkinson A, et al. Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: Defining the perivascular route for the elimination of amyloid A from the human brain. Neuropathol Appl Neurobiol 2003;29:106-17 (Pubitemid 36408329)
11. Shibata M, Yamada S, Kumar SR, et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptorYrelated protein-1 at the blood-brain barrier. J Clin Invest 2000;106:1489-99 (Pubitemid 32038587)
12. Vogelgesang S, Cascorbi I, Schroeder E, et al. Deposition of Alzheimer's A-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 2002; 12:535-41 (Pubitemid 35177083)
13. Lam FC, Liu R, Lu P, et al. A-Amyloid efflux mediated by P-glycoprotein. J Neurochem 2001;76:1121-28
14. Kuhnke D, Jedlitschky G, Grube M, et al. MDR1-P-glycoprotein (ABCB1) mediates transport of Alzheimer's amyloid-A peptidesV implications for the mechanisms of AA clearance at the blood-brain barrier. Brain Pathol 2007;17:347-53 (Pubitemid 47537591)
15. Sagare A, Deane R, Bell RD, et al. Clearance of amyloid-A by circulating lipoprotein receptors. Nat Med 2007;13:1029-31 (Pubitemid 47517512)
16. Rogers J, Lue LF. Microglial chemotaxis, activation, and phagocytosis of amyloid A-peptide as linked phenomena in Alzheimer's disease. Neurochem Int 2001;39:333-40 (Pubitemid 32907397)
17. Saido TC, Iwata N. Metabolism of amyloid A peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy. Neurosci Res 2006;54:235-53 (Pubitemid 43374441)
18. Miners JS, Baig S, Palmer J, et al. AA-degrading enzymes in Alzheimer's disease. Brain Pathol 2008;18:240-52
19. Leissring MA. The AACs of AA-cleaving proteases. J Biol Chem 2008; 283:29645-49
20. Weller RO, Massey A, Newman TA, et al. Cerebral amyloid angiopathy: Amyloid A accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol 1998;153:725-33 (Pubitemid 28419027)
21. Deane R, Sagare A, Zlokovic BV. The role of the cell surface LRP and soluble LRP in blood-brain barrier AA clearance in Alzheimer's disease. Curr Pharm Des 2008;14:1601-5 (Pubitemid 352002987)
22. Deane R, Bell RD, Sagare A, et al. Clearance of amyloid-A peptide across the blood-brain barrier: Implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 2009;8:16-30
23. Miners JS, Kehoe P, Love S. Neprilysin protects against cerebral amyloid angiopathy and AA-induced degeneration of cerebrovascular smooth muscle cells. Brain Pathol 2011;21:594-605
24. Rogers J, Strohmeyer R, Kovelowski CJ, et al. Microglia and inflammatory mechanisms in the clearance of amyloid A peptide. Glia 2002; 40:260-69 (Pubitemid 35337383)
25. Miners JS, Morris S, Love S, Kehoe PG. Accumulation of insoluble amyloid-A in Down's syndrome is associated with increased BACE-1 and neprilysin activities. J Alzheimers Dis 2011;23:101-8
26. Miners JS, Baig S, Tayler H, et al. Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity. J Neuropathol Exp Neurol 2009;68:902-14
27. Yin KJ, Cirrito JR, Yan P, et al. Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-A peptide catabolism. J Neurosci 2006;26:10939-48 (Pubitemid 44772184)
28. Tucker HM, Kihiko M, Caldwell JN, et al. The plasmin system is induced by and degrades amyloid-A aggregates. J Neurosci 2000;20: 3937-46 (Pubitemid 30365663)
29. Leal MC, Dorfman VB, Gamba AF, et al. Plaque-associated overexpression of insulin-degrading enzyme in the cerebral cortex of aged transgenic tg2576 mice with Alzheimer pathology. J Neuropathol Exp Neurol 2006;65:976-87 (Pubitemid 44521798)
30. Wang R, Wang S, Malter JS, et al. Effects of 4-hydroxy-nonenal and amyloid-A on expression and activity of endothelin converting enzyme and insulin degrading enzyme in SH-SY5Y cells. J Alzheimers Dis 2009;17:489-501
31. Palmer JC, Baig S, Kehoe PG, et al. Endothelin-converting enzyme-2 is increased in Alzheimer's disease and up-regulated by AA. Am J Pathol 2009;175:262-70
32. Mueller-Steiner S, Zhou Y, Arai H, et al. Antiamyloidogenic and neuroprotective functions of cathepsin B: Implications for Alzheimer's disease. Neuron 2006;51:703-14 (Pubitemid 44374903)
33. Miners JS, van Helmond Z, Raiker M, et al. ACE variants and association with brain AA levels in Alzheimer's disease. Am J Transl Res 2010;3:73-80
34. Lee JM, Yin KJ, Hsin I, et al. Matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy. Ann Neurol 2003;54:379-82 (Pubitemid 37072041)
35. Jung SS, Zhang W, Van Nostrand WE. Pathogenic AA induces the expression and activation of matrix metalloproteinase-2 in human cerebrovascular smooth muscle cells. J Neurochem 2003;85:1208-15 (Pubitemid 36613269)
36. Deb S, Zhang JW, Gottschall PE. Activated isoforms of MMP-2 are induced in U87 human glioma cells in response to A-amyloid peptide. J Neurosci Res 1999;55:44-53 (Pubitemid 29014410)
37. Selkoe DJ. Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 2001;81:741-66 (Pubitemid 32267077)
38. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 2004;430:631-39 (Pubitemid 39061671)
39. Evin G, Weidemann A. Biogenesis and metabolism of Alzheimer's disease AA amyloid peptides. Peptides 2002;23:1285-97 (Pubitemid 34786707)
40. Lammich S, Kojro E, Postina R, et al. Constitutive and regulated α-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 1999;96:3922-27 (Pubitemid 29169012)
41. Koike H, Tomioka S, Sorimachi H, et al. Membrane-anchored metalloprotease MDC9 has an α-secretase activity responsible for processing the amyloid precursor protein. Biochem J 1999;343(Pt 2):371-75 (Pubitemid 29511770)
42. Buxbaum JD, Liu KN, Luo Y, et al. Evidence that tumor necrosis factor α converting enzyme is involved in regulated α-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 1998;273:27765-67 (Pubitemid 28496060)
43. Jarrett JT, Berger EP, Lansbury PT Jr. The carboxy terminus of the A amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993; 32:4693-97 (Pubitemid 23162022)
44. Love S. Contribution of cerebral amyloid angiopathy to Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75:1-4 (Pubitemid 38091257)
45. Iwata N, Tsubuki S, Takaki Y, et al. Identification of the major AA1-42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition. Nat Med 2000;6:143-50 (Pubitemid 30082357)
46. Iwata N, Tsubuki S, Takaki Y, et al. Metabolic regulation of brain AA by neprilysin. Science 2001;292:1550-52
47. Leissring MA, Farris W, Chang AY, et al. Enhanced proteolysis of A-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003;40:1087-93 (Pubitemid 38032786)
48. Howell S, Nalbantoglu J, Crine P. Neutral endopeptidase can hydrolyze A-amyloid(1-40) but shows no effect on A-amyloid precursor protein metabolism. Peptides 1995;16:647-52
49. Johnson GD, Stevenson T, Ahn K. Hydrolysis of peptide hormones by endothelin-converting enzyme-1. A comparison with neprilysin. J Biol Chem 1999;274:4053-58
50. Sisodia SS. A-Amyloid precursor protein cleavage by a membranebound protease. Proc Natl Acad Sci USA 1992;89:6075-79
51. Eckman EA, Reed DK, Eckman CB. Degradation of the Alzheimer's amyloid A peptide by endothelin-converting enzyme. J Biol Chem 2001; 276:24540-48
52. Mukherjee A, Song E, Kihiko-Ehmann M, et al. Insulysin hydrolyzes amyloid A peptides to products that are neither neurotoxic nor deposit on amyloid plaques. J Neurosci 2000;20:8745-49
53. Kurochkin IV, Goto S. Alzheimer's A-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett 1994;345:33-37
54. Qiu WQ, Walsh DM, Ye Z, et al. Insulin-degrading enzyme regulates extracellular levels of amyloid A-protein by degradation. J Biol Chem 1998;273:32730-38 (Pubitemid 28557658)
55. Vekrellis K, Ye Z, Qiu WQ, et al. Neurons regulate extracellular levels of amyloid A-protein via proteolysis by insulin-degrading enzyme. J Neurosci 2000;20:1657-65 (Pubitemid 30220363)
56. Hu J, Igarashi A, Kamata M, et al. Angiotensin-converting enzyme degrades Alzheimer amyloid A-peptide (AA); retards AA aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 2001;276:47863-68
57. Oba R, Igarashi A, Kamata M, et al. The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid A-peptide. Eur J Neurosci 2005;21:733-40 (Pubitemid 40363508)
58. Sun X, Becker M, Pankow K, et al. Catabolic attacks of membranebound angiotensin-converting enzyme on the N-terminal part of speciesspecific amyloid-A peptides. Eur J Pharmacol 2008;588:18-25
59. Toropygin IY, Kugaevskaya EV, Mirgorodskaya OA, et al. The N-domain of angiotensin-converting enzyme specifically hydrolyzes the Arg-5-His-6 bond of Alzheimer's AA-(1-16) peptide and its isoAsp-7 analogue with different efficiency as evidenced by quantitative matrixassisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 2008;22:231-39 (Pubitemid 351156136)
60. Zou K, Maeda T, Watanabe A, et al. AA42-to-AA40-and angiotensinconverting activities in different domains of angiotensin-converting enzyme. J Biol Chem 2009;284:31914-20
61. Crouch PJ, Tew DJ, Du T, et al. Restored degradation of the Alzheimer's amyloid-A peptide by targeting amyloid formation. J Neurochem 2009;108:1198-207
62. Yamada T, Yoshiyama Y, Sato H, et al. White matter microglia produce membrane-type matrix metalloprotease, an activator of gelatinase A, in human brain tissues. Acta Neuropathol 1995;90:421-24
63. Roher AE, Kasunic TC, Woods AS, et al. Proteolysis of A A peptide from Alzheimer disease brain by gelatinase A. Biochem Biophys Res Commun 1994;205:1755-61
64. Yan P, Hu X, Song H, et al. Matrix metalloproteinase-9 degrades amyloid-A fibrils in vitro and compact plaques in situ. J Biol Chem 2006;281:24566-74 (Pubitemid 44274231)
65. Backstrom JR, Lim GP, Cullen MJ, et al. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-A peptide (1-40). J Neurosci 1996;16: 7910-19 (Pubitemid 26405054)
66. Van Nostrand WE, Porter M. Plasmin cleavage of the amyloid A-protein: Alteration of secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry 1999;38:11570-76
67. Ledesma MD, Da Silva JS, Crassaerts K, et al. Brain plasmin enhances APP α-cleavage and AA degradation and is reduced in Alzheimer's disease brains. EMBO Rep 2000;1:530-35
68. Liao MC, Van Nostrand WE. Degradation of soluble and fibrillar amyloid A-protein by matrix metalloproteinase (MT1-MMP) in vitro. Biochemistry 2010;49:1127-36
69. Liao MC, Ahmed M, Smith SO, et al. Degradation of amyloid A protein by purified myelin basic protein. J Biol Chem 2009;284:28917-25
70. Yamin R, Zhao C, O'Connor PB, et al. Acyl peptide hydrolase degrades monomeric and oligomeric amyloid-A peptide. Mol Neurodegener 2009;4:33
71. Yamin R, Bagchi S, Hildebrant R, et al. Acyl peptide hydrolase, a serine proteinase isolated from conditioned medium of neuroblastoma cells, degrades the amyloid-A peptide. J Neurochem 2007;100:458-67 (Pubitemid 46011006)
72. Huang JY, Bruno AM, Patel CA, et al. Human membrane metalloendopeptidase- like protein degrades both A-amyloid 42 and A-amyloid40 Neuroscience 2008;155:258-62
73. Numata K, Kaplan DL. Mechanisms of enzymatic degradation of amyloid A microfibrils generating nanofilaments and nanospheres related to cytotoxicity. Biochemistry 2010;49:3254-60
74. Carson JA, Turner AJ. A-Amyloid catabolism: Roles for neprilysin (NEP) and other metallopeptidases? J Neurochem 2002;81:1-8 (Pubitemid 34808849)
75. Wang DS, Dickson DW, Malter JS. A-Amyloid degradation and Alzheimer's disease. J Biomed Biotechnol 2006;2006:58406
76. Eckman EA, Eckman CB. AA-degrading enzymes: Modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem Soc Trans 2005;33:1101-5 (Pubitemid 41659123)
77. Ahmed M, Davis J, Aucoin D, et al. Structural conversion of neurotoxic amyloid-A (1-42) oligomers to fibrils. Nat Struct Mol Biol 2010;17: 561-67
78. Fukami S, Watanabe K, Iwata N, et al. AA-degrading endopeptidase, neprilysin, in mouse brain: Synaptic and axonal localization inversely correlating with AA pathology. Neurosci Res 2002;43:39-56 (Pubitemid 34628582)
79. Barnes K, Doherty S, Turner AJ. Endopeptidase-24.11 is the integral membrane peptidase initiating degradation of somatostatin in the hippocampus. J Neurochem 1995;64:1826-32
80. Miners JS, Van Helmond Z, Chalmers K, et al. Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol 2006;65:1012-21 (Pubitemid 44521802)
81. Carpentier M, Robitaille Y, DesGroseillers L, et al. Declining expression of neprilysin in Alzheimer disease vasculature: Possible involvement in cerebral amyloid angiopathy. J Neuropathol Exp Neurol 2002; 61:849-56
82. Huang SM, Mouri A, Kokubo H, et al. Neprilysin-sensitive synapseassociated amyloid-A peptide oligomers impair neuronal plasticity and cognitive function. J Biol Chem 2006;281:17941-51 (Pubitemid 44035593)
83. Kanemitsu H, Tomiyama T, Mori H. Human neprilysin is capable of degrading amyloid A peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci Lett 2003;350:113-16 (Pubitemid 37101425)
84. Skidgel RA, Alhenc-Gelas F, Campbell WB. Prologue: Kinins and related systems. New life for old discoveries. Am J Physiol Heart Circ Physiol 2003;284:H1886-91 (Pubitemid 36622395)
85. Whyteside AR, Turner AJ. Human neprilysin-2 (NEP2) and NEP display distinct subcellular localisations and substrate preferences. FEBS Lett 2008;582:2382-86
86. Rose C, Voisin S, Gros C, et al. Cell-specific activity of neprilysin 2 isoforms and enzymic specificity compared with neprilysin. Biochem J 2002;363:697-705 (Pubitemid 34526390)
87. Ikeda K, Emoto N, Raharjo SB, et al. Molecular identification and characterization of novel membrane-bound metalloprotease, the soluble secreted form of which hydrolyzes a variety of vasoactive peptides. J Biol Chem 1999;274:32469-77
88. Schweizer A, Valdenaire O, Nelbock P, et al. Human endothelinconverting enzyme (ECE-1): Three isoforms with distinct subcellular localizations. Biochem J 1997;328(Pt 3):871-77 (Pubitemid 28005788)
89. Palmer JC, Kehoe PG, Love S. Endothelin-converting enzyme-1 in Alzheimer's disease and vascular dementia. Neuropathol Appl Neurobiol 2010;36:487-97
90. Davenport AP, Kuc RE, Mockridge JW. Endothelin-converting enzyme in the human vasculature: Evidence for differential conversion of big endothelin-3 by endothelial and smooth-muscle cells. J Cardiovasc Pharmacol 1998;31(Suppl 1):S1-S3 (Pubitemid 128709852)
91. Xu D, Emoto N, Giaid A, et al. ECE-1: A membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994;78:473-85 (Pubitemid 24250811)
92. Eckman EA, Watson M, Marlow L, et al. Alzheimer's disease A-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem 2003;278:2081-84 (Pubitemid 36801269)
93. Valdenaire O, Lepailleur-Enouf D, Egidy G, et al. A fourth isoform of endothelin-converting enzyme (ECE-1) is generated from an additional promoter molecular cloning and characterization. Eur J Biochem 1999; 264:341-49 (Pubitemid 29424437)
94. Naidoo V, Naidoo S, Raidoo DM. Immunolocalisation of endothelin-1 in human brain. J Chem Neuroanat 2004;27:193-200 (Pubitemid 38739358)
95. Hoang MV, Turner AJ. Novel activity of endothelin-converting enzyme: Hydrolysis of bradykinin. Biochem J 1997;327:23-26 (Pubitemid 27455455)
96. Davenport AP, Kuc RE. Cellular expression of isoforms of endothelinconverting enzyme-1 (ECE-1c, ECE-1b and ECE-1a) and endothelinconverting enzyme-2. J Cardiovasc Pharmacol 2000;36:S12-14
97. Mzhavia N, Pan H, Che FY, et al. Characterization of endothelinconverting enzyme-2. Implication for a role in the nonclassical processing of regulatory peptides. J Biol Chem 2003;278:14704-11 (Pubitemid 36799793)
98. Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membranebound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem 1995;270:15262-68
99. Savaskan E, Hock C, Olivieri G, et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol Aging 2001;22:541-46 (Pubitemid 32607737)
100. Miners JS, Ashby E, Van Helmond Z, et al. Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 2008;34:181-93 (Pubitemid 351327960)
101. Hemming ML, Selkoe DJ. Amyloid A-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 2005;280:37644-50 (Pubitemid 41642372)
102. Skidgel RA, Erdos EG. Angiotensin converting enzyme (ACE) and neprilysin hydrolyze neuropeptides: A brief history, the beginning and follow-ups to early studies. Peptides 2004;25:521-25 (Pubitemid 38591559)
103. Duckworth WC, Bennett RG, Hamel FG. A direct inhibitory effect of insulin on a cytosolic proteolytic complex containing insulin-degrading enzyme and multicatalytic proteinase. J Biol Chem 1994;269:24575-80 (Pubitemid 24311707)
104. Bennett RG, Duckworth WC, Hamel FG. Degradation of amylin by insulin-degrading enzyme. J Biol Chem 2000;275:36621-25 (Pubitemid 32002062)
105. Akiyama H, Shii K, Yokono K, et al. Cellular localization of insulin insulindegrading enzyme in rat liver using monoclonal antibodies specific for this enzyme. Biochem Biophys Res Commun 1988;155:914-22
106. Cook DG, Leverenz JB, McMillan PJ, et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein ?4 allele. Am J Pathol 2003;162:313-19 (Pubitemid 36042013)
107. Bernstein HG, Ansorge S, Riederer P, et al. Insulin-degrading enzyme in the Alzheimer's disease brain: Prominent localization in neurons and senile plaques. Neurosci Lett 1999;263:161-64 (Pubitemid 29158953)
108. Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: Progress and potential. Endocr Rev 1998;19:608-24 (Pubitemid 28467714)
109. Goldfine ID, Williams JA, Bailey AC, et al. Degradation of insulin by isolated mouse pancreatic acini. Evidence for cell surface protease activity. Diabetes 1984;33:64-72 (Pubitemid 14187205)
110. Misbin RI, Almira EC. Degradation of insulin and insulin-like growth factors by enzyme purified from human erythrocytes. Comparison of degradation products observed with A14-and B26-[125I] monoiodoinsulin. Diabetes 1989;38:152-58 (Pubitemid 19054794)
111. Bulloj A, Leal MC, Xu H, et al. Insulin-degrading enzyme sorting in exosomes: A secretory pathway for a key brain amyloid-A degrading protease. J Alzheimers Dis 2010;19:79-95
112. Morelli L, Llovera R, Gonzalez SA, et al. Differential degradation of amyloid A genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme. J Biol Chem 2003;278:23221-26 (Pubitemid 36830134)
113. Walsh DM, Klyubin I, Fadeeva JV, et al. Amyloid-A oligomers: Their production, toxicity and therapeutic inhibition. Biochem Soc Trans 2002;30:552-57 (Pubitemid 35001597)
114. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid A-protein, and the A-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 2003;100:4162-67 (Pubitemid 36418174)
115. Morita M, Kurochkin IV, Motojima K, et al. Insulin-degrading enzyme exists inside of rat liver peroxisomes and degrades oxidized proteins. Cell Struct Funct 2000;25:309-15 (Pubitemid 32171027)
116. Morelli L, Llovera RE, Mathov I, et al. Insulin-degrading enzyme in brain microvessels: Proteolysis of amyloid {A} vasculotropic variants and reduced activity in cerebral amyloid angiopathy. J Biol Chem 2004; 279:56004-13 (Pubitemid 40066608)
117. Lynch JA, George AM, Eisenhauer PB, et al. Insulin degrading enzyme is localized predominantly at the cell surface of polarized and unpolarized human cerebrovascular endothelial cell cultures. J Neurosci Res 2006;83:1262-70 (Pubitemid 43668009)
118. Seta KA, Roth RA, Gottschail PE. Overexpression of insulin degrading enzyme: Cellular localization and effects on insulin signaling. Biochem Biophys Res Commun 1997;231:167-71 (Pubitemid 27212131)
119. Deb S, Wenjun Zhang J, et al. A-Amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes. Brain Res 2003;970:205-13 (Pubitemid 36423196)
120. Baig S, Kehoe PG, Love S. MMP-2,-3 and-9 levels and activity are not related to AA load in the frontal cortex in Alzheimer's disease. Neuropathol Appl Neurobiol 2008;34:205-15 (Pubitemid 351327964)
121. Hernandez-Guillamon M, Mawhirt S, Fossati S, et al. Matrix metalloproteinase 2 (MMP-2) degrades soluble vasculotropic amyloid-A E22Q and L34V mutants, delaying their toxicity for human brain microvascular endothelial cells. J Biol Chem 2010;285:27144-58
122. Cheifetz S, Boggs JM, Moscarello MA. Increase in vesicle permeability mediated by myelin basic protein: Effect of phosphorylation of basic protein. Biochemistry 1985;24:5170-75 (Pubitemid 15242623)
123. D'Souza CA, Wood DD, She YM, et al. Autocatalytic cleavage of myelin basic protein: An alternative to molecular mimicry. Biochemistry 2005;44:12905-13 (Pubitemid 41377330)
124. Barker R, Love S, Kehoe PG. Plasminogen and plasmin in Alzheimer's disease. Brain Res 2010;1355:7-15
125. Linebaugh BE, Sameni M, Day NA, et al. Exocytosis of active cathepsin B enzyme activity at pH 7.0, inhibition and molecular mass. Eur J Biochem 1999;264:100-9 (Pubitemid 29385872)
126. Rawlings ND, Barrett AJ, Bateman A. MEROPS: The peptidase database. Nucleic Acids Res 2010;38:D227-33
127. Turner AJ, Tanzawa K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J 1997;11:355-64 (Pubitemid 27193940)
128. Turner AJ, Isaac RE, Coates D. The neprilysin (NEP) family of zinc metalloendopeptidases: Genomics and function. Bioessays 2001;23:261-69 (Pubitemid 32192145)
129. Turner AJ, Brown CD, Carson JA, et al. The neprilysin family in health and disease. Adv Exp Med Biol 2000;477:229-40 (Pubitemid 32174009)
130. Dahlgren KN, Manelli AM, Stine WB Jr, et al. Oligomeric and fibrillar species of amyloid-A peptides differentially affect neuronal viability. J Biol Chem 2002;277:32046-53 (Pubitemid 34969015)
131. Townsend M, Shankar GM, Mehta T, et al. Effects of secreted oligomers of amyloid A-protein on hippocampal synaptic plasticity: A potent role for trimers. J Physiol 2006;572:477-92
132. Shankar GM, Li S, Mehta TH, et al. Amyloid-A protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008;14:837-42
133. Lesne S, Koh MT, Kotilinek L, et al. A specific amyloid-A protein assembly in the brain impairs memory. Nature 2006;440:352-57
134. Xia W, Yang T, Shankar G, et al. A specific enzyme-linked immunosorbent assay for measuring A-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol 2009;66:190-99
135. van Helmond Z, Miners JS, Kehoe PG, Love S. Oligomeric AA in Alzheimer's disease: Relationship to plaque and tangle pathology, APOE genotype and cerebral amyloid angiopathy. Brain Pathol 2010; 20:468-80
136. Hyman BT. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol 2011;68:1062-64
137. Morelli L, Llovera RE, Alonso LG, et al. Insulin-degrading enzyme degrades amyloid peptides associated with British and Danish familial dementia. Biochem Biophys Res Commun 2005;332:808-16 (Pubitemid 40745185)
138. Yang CN, Shiao YJ, Shie FS, et al. Mechanism mediating oligomeric AA clearance by naive primary microglia. Neurobiol Dis 2011;42: 221-30
139. Chimon S, Shaibat MA, Jones CR, et al. Evidence of fibril-like A-sheet structures in a neurotoxic amyloid intermediate of Alzheimer's A-amyloid. Nat Struct Mol Biol 2007;14:1157-64 (Pubitemid 350223342)
140. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, et al. Structureactivity analyses of A-amyloid peptides: Contributions of the A 25-35 region to aggregation and neurotoxicity. J Neurochem 1995;64:253-65
141. Hull M, Muksch B, Akundi RS, et al. Amyloid A peptide (25-35) activates protein kinase C leading to cyclooxygenase-2 induction and prostaglandin E2 release in primary midbrain astrocytes. Neurochem Int 2006;48:663-72
142. Misiti F, Sampaolese B, Pezzotti M, et al. AA(31-35) peptide induce apoptosis in PC 12 cells: Contrast with AA(25-35) peptide and examination of underlying mechanisms. Neurochem Int 2005;46:575-83 (Pubitemid 40552799)
143. Liu R, McAllister C, Lyubchenko Y, et al. Residues 17-20 and 30-35 of A-amyloid play critical roles in aggregation. J Neurosci Res 2004;75: 162-71 (Pubitemid 38049387)
144. Shirotani K, Tsubuki S, Iwata N, et al. Neprilysin degrades both amyloid A peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan-and phosphoramidon-sensitive endopeptidases. J Biol Chem 2001;276:21895-901
145. Hafez D, Huang JY, Huynh AM, et al. Neprilysin-2 is an important A-amyloid degrading enzyme. Am J Pathol 2011;178:306-12
146. Miller BC, Eckman EA, Sambamurti K, et al. Amyloid-A peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc Natl Acad Sci USA 2003;100:6221-26 (Pubitemid 36576957)
147. Nisemblat Y, Belinson H, Dolev I, Michaelson DM. Activation of the amyloid cascade by intracerebroventricular injection of the protease inhibitor phosphoramidon. Neurodegener Dis 2008;5:166-69 (Pubitemid 351347840)
148. Tucker HM, Simpson J, Kihiko-Ehmann M, et al. Plasmin deficiency does not alter endogenous murine amyloid A levels in mice. Neurosci Lett 2004;368:285-89 (Pubitemid 39214969)
149. Hemming ML, Selkoe DJ, Farris W. Effects of prolonged angiotensinconverting enzyme inhibitor treatment on amyloid A-protein metabolism in mouse models of Alzheimer disease. Neurobiol Dis 2007;26:273-81 (Pubitemid 46436503)
150. Eckman EA, Adams SK, Troendle FJ, et al. Regulation of steady-state A-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem 2006;281: 30471-78 (Pubitemid 44582103)
151. Madani R, Poirier R, Wolfer DP, et al. Lack of neprilysin suffices to generate murine amyloid-like deposits in the brain and behavioral deficit in vivo. J Neurosci Res 2006;84:1871-78 (Pubitemid 44892621)
152. Farris W, Schutz SG, Cirrito JR, et al. Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol 2007;171:241-51 (Pubitemid 47339241)
153. Zou LB, Mouri A, Iwata N, et al. Inhibition of neprilysin by infusion of thiorphan into the hippocampus causes an accumulation of amyloid-A and impairment of learning and memory. J Pharmacol Exp Ther 2006; 317:334-40
154. Mouri A, Zou LB, Iwata N, et al. Inhibition of neprilysin by thiorphan (i.c.v.) causes an accumulation of amyloid A and impairment of learning and memory. Behav Brain Res 2006;168:83-91 (Pubitemid 43152056)
155. Poirier R, Wolfer DP, Welzl H, et al. Neuronal neprilysin overexpression is associated with attenuation of AA-related spatial memory deficit. Neurobiol Dis 2006;24:475-83 (Pubitemid 44716677)
156. Meilandt WJ, Cisse M, Ho K, et al. Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic AA oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J Neurosci 2009;29:1977-86
157. Saito T, Iwata N, Tsubuki S, et al. Somatostatin regulates brain amyloid A peptide AA42 through modulation of proteolytic degradation. Nat Med 2005;11:434-39 (Pubitemid 40562335)
158. Lazarov O, Robinson J, Tang YP, et al. Environmental enrichment reduces AA levels and amyloid deposition in transgenic mice. Cell 2005;120:701-13 (Pubitemid 40343081)
159. Marr RA, Rockenstein E, Mukherjee A, et al. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci 2003; 23:1992-96 (Pubitemid 36368884)
160. Iwata N, Mizukami H, Shirotani K, et al. Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-A peptide in mouse brain. J Neurosci 2004;24:991-98 (Pubitemid 38146610)
161. Spencer B, Marr RA, Rockenstein E, et al. Long-term neprilysin gene transfer is associated with reduced levels of intracellular AA and behavioral improvement in APP transgenic mice. BMC Neurosci 2008; 9:109
162. El-Amouri SS, Zhu H, Yu J, et al. Neprilysin: An enzyme candidate to slow the progression of Alzheimer's disease. Am J Pathol 2008;172: 1342-54 (Pubitemid 351671547)
163. Yasojima K, Akiyama H, McGeer EG, et al. Reduced neprilysin in high plaque areas of Alzheimer brain: A possible relationship to deficient degradation of A-amyloid peptide. Neurosci Lett 2001;297:97-100
164. Russo R, Borghi R, Markesbery W, et al. Neprylisin decreases uniformly in Alzheimer's disease and in normal aging. FEBS Lett 2005; 579:6027-30 (Pubitemid 41546241)
165. Akiyama H, Kondo H, Ikeda K, et al. Immunohistochemical localization of neprilysin in the human cerebral cortex: Inverse association with vulnerability to amyloid A-protein (AA) deposition. Brain Res 2001; 902:277-81 (Pubitemid 32510877)
166. Wang S, Wang R, Chen L, et al. Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain. J Neurochem 2010;115:47-57
167. Wang DS, Lipton RB, Katz MJ, et al. Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. J Neuropathol Exp Neurol 2005;64:378-85 (Pubitemid 40629127)
168. Hellstrom-Lindahl E, Ravid R, Nordberg A. Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: Inverse correlation with AA levels. Neurobiol Aging 2008;29:210-21
169. Miners JS, Verbeek MM, Rikkert MO, et al. Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid. J Neurosci Methods 2008;167:229-36 (Pubitemid 350245527)
170. Miners JS, Kehoe PG, Love S. Immunocapture-based fluorometric assay for the measurement of insulin-degrading enzyme activity in brain tissue homogenates. J Neurosci Methods 2008;169:177-81
171. Miners JS, van Helmond Z, Kehoe PG, et al. Changes with age in the activities of A-secretase and the AA-degrading enzymes neprilysin, insulin-degrading enzyme and angiotensin-converting enzyme. Brain Pathol 2010;20:794-802
172. Maruyama M, Higuchi M, Takaki Y, et al. Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease. Ann Neurol 2005; 57:832-42 (Pubitemid 40798621)
173. Bruno MA, Mufson EJ, Wuu J, et al. Increased matrix metalloproteinase 9 activity in mild cognitive impairment. J Neuropathol Exp Neurol 2009;68:1309-18
174. Sundelof J, Sundstrom J, Hansson O, et al. Higher cathepsin B levels in plasma in Alzheimer's disease compared to healthy controls. J Alzheimers Dis 2010;22:1223-30
175. Gan L, Ye S, Chu A, et al. Identification of cathepsin B as a mediator of neuronal death induced by AA-activated microglial cells using a functional genomics approach. J Biol Chem 2004;279:5565-72 (Pubitemid 38220582)
176. Wang R, Wang S, Malter JS, et al. Effects of HNE-modification induced by AA on neprilysin expression and activity in SH-SY5Y cells. J Neurochem 2009;108:1072-82
177. Mohajeri MH, Wollmer MA, Nitsch RM. AA42-induced increase in neprilysin is associated with prevention of amyloid plaque formation in vivo. J Biol Chem 2002;277:35460-65
178. Mohajeri MH, Kuehnle K, Li H, et al. Anti-amyloid activity of neprilysin in plaque-bearing mouse models of Alzheimer's disease. FEBS Lett 2004;562:16-21 (Pubitemid 38388441)
179. Vepsalainen S, Hiltunen M, Helisalmi S, et al. Increased expression of AA degrading enzyme IDE in the cortex of transgenic mice with Alzheimer's disease-like neuropathology. Neurosci Lett 2008;438:216-20
180. Revesz T, Holton JL, Lashley T, et al. Sporadic and familial cerebral amyloid angiopathies. Brain Pathol 2002;12:343-57 (Pubitemid 34743217)
181. Revesz T, Ghiso J, Lashley T, et al. Cerebral amyloid angiopathies: A pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol 2003;62:885-98 (Pubitemid 37159029)
182. Love S, Miners S, Palmer J, et al. Insights into the pathogenesis and pathogenicity of cerebral amyloid angiopathy. Front Biosci 2009;14: 4778-92
183. Keage HA, Carare RO, Friedland RP, et al. Population studies of sporadic cerebral amyloid angiopathy and dementia: A systematic review. BMC Neurol 2009;9:3
184. Van Dorpe J, Smeijers L, Dewachter I, et al. Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons. Am J Pathol 2000;157:1283-98
185. Calhoun ME, Burgermeister P, Phinney AL, et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci USA 1999; 96:14088-93
186. Burgermeister P, Calhoun ME, Winkler DT, et al. Mechanisms of cerebrovascular amyloid deposition. Lessons from mouse models. Ann N Y Acad Sci 2000;903:307-16 (Pubitemid 30251571)
187. Gravina SA, Ho L, Eckman CB, et al. Amyloid A protein (AA) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at AA40 or AA42(43). J Biol Chem 1995;270:7013-16
188. Weller RO, Boche D, Nicoll JA. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathol 2009;118:87-102
189. Hawkes CA, Hartig W, Kacza J, et al. Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathol 2011;121:431-43
190. Van Nostrand WE, Davis-Salinas J, Saporito-Irwin SM. Amyloid A-protein induces the cerebrovascular cellular pathology of Alzheimer's disease and related disorders. Ann N Y Acad Sci 1996;777:297-302 (Pubitemid 26149205)
191. Ruzali W, Kehoe P, Love S. LRP-1Ymediated uptake of AA by cerebrovascular smooth muscle cells: Relationship to cytotoxicity. Neuropathol Appl Neurobiol 2011;37:10
192. Lee CY, Landreth GE. The role of microglia in amyloid clearance from the AD brain. J Neural Transm 2010;117:949-60
193. Simard AR, Soulet D, Gowing G, et al. Bone marrowYderived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 2006;49:489-502 (Pubitemid 43221886)
194. Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective A-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci 2008;28:8354-60
195. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid A-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916-19 (Pubitemid 30644751)
196. Bard F, Barbour R, Cannon C, et al. Epitope and isotype specificities of antibodies to A-amyloid peptide for protection against Alzheimer's diseaseYlike neuropathology. Proc Natl Acad Sci USA 2003;100: 2023-28 (Pubitemid 36254567)
197. Das P, Howard V, Loosbrock N, et al. Amyloid-A immunization effectively reduces amyloid deposition in FcRFj/j knock-out mice. J Neurosci 2003;23:8532-38 (Pubitemid 37158753)
198. Bacskai BJ, Kajdasz ST, McLellan ME, et al. NonYFc-mediated mechanisms are involved in clearance of amyloid-A in vivo by immunotherapy. J Neurosci 2002;22:7873-78 (Pubitemid 35379092)
199. Wilcock DM, DiCarlo G, Henderson D, et al. Intracranially administered anti-AA antibodies reduce A-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci 2003;23:3745-51 (Pubitemid 36958481)
200. Nicoll JA, Barton E, Boche D, et al. AA species removal after AA42 immunization. J Neuropathol Exp Neurol 2006;65:1040-48
201. Walker DG, Lue LF, Beach TG. Gene expression profiling of amyloid A peptideYstimulated human post-mortem brain microglia. Neurobiol Aging 2001;22:957-66 (Pubitemid 34066564)
202. Liu B, Hong JS. Role of microglia in inflammation-mediated neurodegenerative diseases: Mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 2003;304:1-7 (Pubitemid 36008905)
203. El Khoury JB, Moore KJ, Means TK, et al. CD36 mediates the innate host response to A-amyloid. J Exp Med 2003;197:1657-66 (Pubitemid 36745341)
204. Bamberger ME, Harris ME, McDonald DR, et al. A cell surface receptor complex for fibrillar A-amyloid mediates microglial activation. J Neurosci 2003;23:2665-74 (Pubitemid 36418601)
205. Kreutzberg GW. Microglia: A sensor for pathological events in the CNS. Trends Neurosci 1996;19:312-18 (Pubitemid 26349059)
206. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3:23-35 (Pubitemid 37328697)
207. Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillar A-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci 2005;25:8240-49 (Pubitemid 41292118)
208. Escribano L, Simon AM, Gimeno E, et al. Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: Mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 2010;35: 1593-604
209. Heneka MT, Nadrigny F, Regen T, et al. Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci USA 2010;107:6058-63
210. Wyss-Coray T, Lin C, Yan F, et al. TGF-A1 promotes microglial amyloid-A clearance and reduces plaque burden in transgenic mice. Nat Med 2001;7:612-18 (Pubitemid 32448330)
211. Shimizu E, Kawahara K, Kajizono M, et al. IL-4Yinduced selective clearance of oligomeric A-amyloid peptide(1-42) by rat primary type 2 microglia. J Immunol 2008;181:6503-13
212. Paresce DM, Ghosh RN, Maxfield FR. Microglial cells internalize aggregates of the Alzheimer's disease amyloid A-protein via a scavenger receptor. Neuron 1996;17:553-65 (Pubitemid 26322226)
213. Koenigsknecht J, Landreth G. Microglial phagocytosis of fibrillar A-amyloid through a A1 integrinYdependent mechanism. J Neurosci 2004;24:9838-46 (Pubitemid 39463564)
214. Frautschy SA, Yang F, Irrizarry M, et al. Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 1998;152:307-17 (Pubitemid 28028071)
215. D'Andrea MR, Cole GM, Ard MD. The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. Neurobiol Aging 2004;25:675-83 (Pubitemid 38686491)
216. Paresce DM, Chung H, Maxfield FR. Slow degradation of aggregates of the Alzheimer's disease amyloid A-protein by microglial cells. J Biol Chem 1997;272:29390-97 (Pubitemid 27498234)
217. Chung H, Brazil MI, Soe TT, et al. Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid A-peptide by microglial cells. J Biol Chem 1999;274:32301-8
218. Majumdar A, Cruz D, Asamoah N, et al. Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. Mol Biol Cell 2007;18:1490-96 (Pubitemid 46626644)
219. Wang PH, Do YS, Macaulay L, et al. Identification of renal cathepsin B as a human prorenin-processing enzyme. J Biol Chem 1991;266: 12633-38 (Pubitemid 21907142)
220. Schwartz W, Bird JW. Degradation of myofibrillar proteins by cathepsins B and D. Biochem J 1977;167:811-20 (Pubitemid 8240997)
221. McDermott JR, Gibson AM. Degradation of Alzheimer's A-amyloid protein by human cathepsin D. Neuroreport 1996;7:2163-66 (Pubitemid 26361838)
222. Hamazaki H. Cathepsin D is involved in the clearance of Alzheimer's A-amyloid protein. FEBS Lett 1996;396:139-42 (Pubitemid 26377812)
223. Mandrekar S, Jiang Q, Lee CY, et al. Microglia mediate the clearance of soluble AA through fluid phase macropinocytosis. J Neurosci 2009;29: 4252-62
224. Tamboli IY, Barth E, Christian L, et al. Statins promote the degradation of extracellular amyloid {A}-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion. J Biol Chem 2010;285:37405-14
225. Kong Y, Ruan L, Qian L, et al. Norepinephrine promotes microglia to uptake and degrade amyloid A peptide through upregulation of mouse formyl peptide receptor 2 and induction of insulin-degrading enzyme. J Neurosci 2010;30:11848-57
226. Iwata N, Higuchi M, Saido TC. Metabolism of amyloid-A peptide and Alzheimer's disease. Pharmacol Ther 2005;108:129-48 (Pubitemid 41527082)
227. Kumar U. Expression of somatostatin receptor subtypes (SSTR1-5) in Alzheimer's disease brain: An immunohistochemical analysis. Neuroscience 2005;134:525-38 (Pubitemid 41111781)
228. Gahete MD, Rubio A, Duran-Prado M, et al. Expression of somatostatin, cortistatin, and their receptors, as well as dopamine receptors, but not of neprilysin, are reduced in the temporal lobe of Alzheimer's disease patients. J Alzheimers Dis 2010;20:465-75
229. Burgos-Ramos E, Hervas-Aguilar A, Aguado-Llera D, et al. Somatostatin and Alzheimer's disease. Mol Cell Endocrinol 2008;286:104-11
230. Aguado-Llera D, Arilla-Ferreiro E, Campos-Barros A, et al. Protective effects of insulin-like growth factor-I on the somatostatinergic system in the temporal cortex of A-amyloidYtreated rats. J Neurochem 2005;92: 607-15 (Pubitemid 40189463)
231. Burgos-Ramos E, Puebla-Jimenez L, Arilla-Ferreiro E. Minocycline prevents AA(25-35)Yinduced reduction of somatostatin and neprilysin content in rat temporal cortex. Life Sci 2009;84:205-10
232. Burgos-Ramos E, Martos-Moreno GA, Lopez MG, et al. The N-terminal tripeptide of insulin-like growth factor-I protects against A-amyloidY induced somatostatin depletion by calcium and glycogen synthase kinase 3A modulation. J Neurochem 2009;109:360-70
233. Pardossi-Piquard R, Petit A, Kawarai T, et al. Presenilin-dependent transcriptional control of the AA-degrading enzyme neprilysin by intracellular domains of AAPP and APLP. Neuron 2005;46:541-54 (Pubitemid 40797380)
234. Belyaev ND, Nalivaeva NN, Makova NZ, et al. Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: Implications for Alzheimer disease. EMBO Rep 2009;10:94-100
235. Eisele YS, Baumann M, Klebl B, et al. Gleevec increases levels of the amyloid precursor protein intracellular domain and of the amyloid-A degrading enzyme neprilysin. Mol Biol Cell 2007;18:3591-600 (Pubitemid 47378696)
236. Morrison BE, Majdzadeh N, D'Mello SR. Histone deacetylases: Focus on the nervous system. Cell Mol Life Sci 2007;64:2258-69 (Pubitemid 47347953)
237. Pulukuri SM, Estes N, Patel J, et al. Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. Cancer Res 2007;67:930-39
238. Peterson GM, Naunton M. Valproate: A simple chemical with so much to offer. J Clin Pharm Ther 2005;30:417-21 (Pubitemid 41603013)
239. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994;140:256-61 (Pubitemid 24231911)
240. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348: 429-32 (Pubitemid 26267873)
241. Liang K, Yang L, Yin C, et al. Estrogen stimulates degradation of A-amyloid peptide by up-regulating neprilysin. J Biol Chem 2010;285: 935-42
242. Yang L, Xu S, Liu C, et al. In vivo metabolism study of ginsenoside Re in rat using high-performance liquid chromatography coupled with tandem mass spectrometry. Anal Bioanal Chem 2009;395:1441-51
243. Ayoub S, Melzig MF. Induction of neutral endopeptidase (NEP) activity of SK-N-SH cells by natural compounds from green tea. J Pharm Pharmacol 2006;58:495-501
244. Melzig MF, Escher F. Induction of neutral endopeptidase and angiotensinconverting enzyme activity of SK-N-SH cells in vitro by quercetin and resveratrol. Pharmazie 2002;57:556-58
245. Nilsson P, Iwata N, Muramatsu S, et al. Gene therapy in Alzheimer's diseaseVpotential for disease modification. J Cell Mol Med 2010;14: 741-57
246. Liu Y, Studzinski C, Beckett T, et al. Circulating neprilysin clears brain amyloid. Mol Cell Neurosci 2010;45:101-7
247. Lebson L, Nash K, Kamath S, et al. Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. J Neurosci 2010;30:9651-58
248. Spencer B, Marr RA, Gindi R, et al. Peripheral delivery of a CNS targeted, metalo-protease reduces AA toxicity in a mouse model of Alzheimer's disease. PLoS One 2011;6:e16575
249. Lowenstein PR, Mandel RJ, Xiong WD, et al. Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: The role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr Gene Ther 2007;7:347-60 (Pubitemid 47595777)
250. Iijima-Ando K, Hearn SA, Granger L, et al. Overexpression of neprilysin reduces Alzheimer amyloid-A42 (AA42)Yinduced neuron loss and intraneuronal AA42 deposits but causes a reduction in cAMP-responsive element-binding proteinYmediated transcription, age-dependent axon pathology, and premature death in Drosophila. J Biol Chem 2008;283: 19066-76
251. Walther T, Albrecht D, Becker M, et al. Improved learning and memory in aged mice deficient in amyloid A-degrading neutral endopeptidase. PLoS One 2009;4:e4590
252. Wisner A, Dufour E, Messaoudi M, et al. Human opiorphin, a natural antinociceptive modulator of opioid-dependent pathways. Proc Natl Acad Sci USA 2006;103:17979-84 (Pubitemid 44852271)
253. Hemming ML, Patterson M, Reske-Nielsen C, et al. Reducing amyloid plaque burden via ex vivo gene delivery of an AA-degrading protease: A novel therapeutic approach to Alzheimer disease. PLoS Med 2007;4: e262
254. Guan H, Liu Y, Daily A, et al. Peripherally expressed neprilysin reduces brain amyloid burden: A novel approach for treating Alzheimer's disease. J Neurosci Res 2009;87:1462-73
255. Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005;11: 551-55 (Pubitemid 40691288)
256. Richardson RM, Varenika V, Forsayeth JR, et al. Future applications: Gene therapy. Neurosurg Clin N Am 2009;20:205-10
257. Tomanin R, Scarpa M. Why do we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction. Curr Gene Ther 2004;4:357-72 (Pubitemid 39534752)
258. Sands MS, Haskins ME. CNS-directed gene therapy for lysosomal storage diseases. Acta Paediatr Suppl 2008;97:22-27 (Pubitemid 351421300)
259. Bobo RH, Laske DW, Akbasak A, et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994;91: 2076-80 (Pubitemid 24092045)
260. Patel SJ, Shapiro WR, Laske DW, et al. Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: Initial experience in 51 patients. Neurosurgery 2005;56:1243-52, discussion 52-3 (Pubitemid 40770440)
261. Patel NK, Gill SS. GDNF delivery for Parkinson's disease. Acta Neurochir Suppl 2007;97:135-54
262. Love S, Plaha P, Patel NK, et al. Glial cell lineYderived neurotrophic factor induces neuronal sprouting in human brain. Nat Med 2005;11: 703-4 (Pubitemid 41021193)
263. Lonser RR, Schiffman R, Robison RA, et al. Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease. Neurology 2007;68:254-61 (Pubitemid 46148336)
264. Kunwar S, Chang SM, Prados MD, et al. Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. Neurosurg Focus 2006;20:E15
265. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell lineYderived neurotrophic factor in Parkinson disease. Nat Med 2003;9: 589-95 (Pubitemid 36597106)
266. Lonser RR, Walbridge S, Murray GJ, et al. Convection perfusion of glucocerebrosidase for neuronopathic Gaucher's disease. Ann Neurol 2005;57:542-48 (Pubitemid 40471164)
267. Zirzow GC, Sanchez OA, Murray GJ, et al. Delivery, distribution, and neuronal uptake of exogenous mannose-terminal glucocerebrosidase in the intact rat brain. Neurochem Res 1999;24:301-5 (Pubitemid 29067974)
268. Lieberman DM, Laske DW, Morrison PF, et al. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 1995;82:1021-29
269. Kroll RA, Pagel MA, Muldoon LL, et al. Increasing volume of distribution to the brain with interstitial infusion: Dose, rather than convection, might be the most important factor. Neurosurgery 1996;38:746-52, discussion 52-4
270. Krauze MT, Saito R, Noble C, et al. Effects of the perivascular space on convection-enhanced delivery of liposomes in primate putamen. Exp Neurol 2005;196:104-11 (Pubitemid 41416652)
271. Varenika V, Kells AP, Valles F, et al. Controlled dissemination of AAV vectors in the primate brain. Prog Brain Res 2009;175:163-72
272. Carare RO, Bernardes-Silva M, Newman TA, et al. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: Significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol Appl Neurobiol 2008;34:131-44 (Pubitemid 351327967)
273. Weller RO, Subash M, Preston SD, et al. Perivascular drainage of amyloid-A peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 2008;18:253-66 (Pubitemid 351430402)
274. Weller RO, Djuanda E, Yow HY, et al. Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol 2009;117:1-14
275. Habisch HJ, Schmid B, von Arnim CA, et al. Efficient processing of Alzheimer's disease amyloid-A peptides by neuroectodermally converted mesenchymal stem cells. Stem Cells Dev 2010;19:629-33
276. Lindvall O, Kokaia Z. Stem cells in human neurodegenerative disordersV time for clinical translation? J Clin Invest 2010;120:29-40
277. Lindvall O, Kokaia Z. Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease. Trends Pharmacol Sci 2009; 30:260-67
278. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of AA42 immunisation in Alzheimer's disease: Follow-up of a randomised, placebocontrolled phase I trial. Lancet 2008;372:216-23 (Pubitemid 351978111)